| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 12/21/2006 | US20060287358 Treatment of CNS disorders associated with mutations in genes encoding lysosomal enzymes |
| 12/21/2006 | US20060287357 Compounds are substituted 8-phenoxy-3-(bicyclo)alkyl-1,2,4-triazolo(4,3-a)pyridines; diabetes, hyperglycemia, obesity, dyslipidemia, hypertension, cognitive impairment, rheumatoid arthritis, glaucoma |
| 12/21/2006 | US20060287356 Thienopyridones as AMPK activators for the treatment of diabetes and obesity |
| 12/21/2006 | US20060287355 Imidazo and thiazolopyridines as jak3 kinase inhibitors |
| 12/21/2006 | US20060287354 Azaindole compounds as kinase inhibitors |
| 12/21/2006 | US20060287353 Method for preventing or treating ischemia-or hemorrhage-induced brain damage using a macrolide compound |
| 12/21/2006 | US20060287352 Modified release compositions comprising tacrolimus |
| 12/21/2006 | US20060287351 Antibiotic cycloalkyltetrahydroquinoline derivatives |
| 12/21/2006 | US20060287350 Process for making cabergoline |
| 12/21/2006 | US20060287349 Benzimidazolyl- or N-hetero analog derivatives of 4-aza-5 alpha -androstan-3-ones, e.g., beta -(1H-imidazo[4,5-c]pyridin-2-yl)-4-methyl-4-aza-5 alpha -androst-1-en-3-one; treatment of conditions caused by androgen deficiency |
| 12/21/2006 | US20060287348 N-(pyridin-2-ylmethyl)-4-methyl-3-oxo-4-aza-5 alpha -androst-1-en-17 beta -acetamide; enhancement of weakened muscle tone; osteoporosis, bone disorders; ; periodontal disease, frailty, aging skin, male hypogonadism, postmenopausal symptoms, inflammatory arthritis, cachexia, Alzheimer's disease |
| 12/21/2006 | US20060287347 Methods for treating smooth muscle disorders using trospium |
| 12/21/2006 | US20060287346 Pharmaceutical formulation comprising a pyrimidine-a-one derivative coated with an enteric polymer |
| 12/21/2006 | US20060287345 Substituted 4-phenyl-4-[1h-imidazol-2-yl]-piperidine derivatives as selective non-peptide delta opiod agonists with antidepressant and anxiolytic activity |
| 12/21/2006 | US20060287344 Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
| 12/21/2006 | US20060287343 vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), receptor antagonists, such as N-(3-Fluoro-4-(2- (thiophen-2-yl)thieno[3,2- b]pyridin-7- yloxy)phenylcarbamothio- yl)-2-phenylacetamide, used for treating angiogenesis-mediated cell proliferative diseases or as antitumor agents |
| 12/21/2006 | US20060287342 Triazolopyrimidine heterocycles as cannabinoid receptor modulators |
| 12/21/2006 | US20060287341 2-substituted 7-aryl-[1,2,4]triazolo[4,3-c]pyrimidin-3(2H)-one; mitogen-activated protein kinase inhibitor; physiological and psychotropic effects including regulation of appetite, immunosuppression, analgesia, inflammation, emesis, anti-nocioception, sedation, and intraocular pressure |
| 12/21/2006 | US20060287340 e.g. 5-(4-fluorophenyl)-N-[2-(1-methyl-2-oxo-1,7-diazaspiro[4,4]nonan-7-yl)-6-quinolinyl]-2-pyrimidinecarboxamide; melanin concentrating hormone receptor antagonist; central nervous system disorders, cardiovascular disorders and metabolic disorders |
| 12/21/2006 | US20060287339 Aza- and polyazanthranyl amides and their use as medicaments |
| 12/21/2006 | US20060287338 Metalloproteinase inhibitor compounds |
| 12/21/2006 | US20060287337 Using ubiquitin ligase inhibitor to treat and prevent cell proliferative, nervous system and/or viral infection, |
| 12/21/2006 | US20060287336 S-methyl-dihydro-ziprasidone for treatment of psychiatric and ocular disorders |
| 12/21/2006 | US20060287335 Serotonergic agents for treating sexual dysfunction |
| 12/21/2006 | US20060287334 e.g. 8-(4-(4-Fluorobenzyl)-piperazin-1-yl)-3-phenylsulfonylquinoline; serotonin receptor modulator; antidepressant, anxiolytic agent, cognition activator; schizophrenia, obesity, Alzheimer's disease |
| 12/21/2006 | US20060287333 -4-substituted-N-(2-(4-(2,3-dihydro-benzo(1,4)dioxin-5-yl)-piperazin -1-yl)propy l)-N-pyridin-2-yl-benzamide or salts; 5-HT1A receptor antagonists; urinary incontinence |
| 12/21/2006 | US20060287332 Melanocortin Receptor-Specific Piperazine and Keto-Piperazine Compounds |
| 12/21/2006 | US20060287331 Melanocortin receptor-specific piperazine compounds with diamine groups |
| 12/21/2006 | US20060287330 Agonist or antgonist and binders and inversion of agonist; use in the treatment of metabolic, immune, infection-related and melanocortin receptor mediated disorders including specifically treatment of obesity and related conditions |
| 12/21/2006 | US20060287329 Novel inhibitor of FXa that can be administered orally; less toxic; enzyme selectivity; high bioavailability; treatment of diseases caused by thrombi or emboli; N-(5-Chloropyridin-2-yl)-5-methoxy-2-({[trans-4-(3-oxomorpholin-4-yl)cyclohexyl]carbonyl}amino)benzamide |
| 12/21/2006 | US20060287327 androgen-dependent diseases, such as prostate cancer, benign prostatic hyperplasia, polycystic ovarian syndrome, acne, hirsutism, seborrhea, androgenic alopecia and male baldness; LHRH (luteinizing hormone-releasing hormone) modulator |
| 12/21/2006 | US20060287326 17-Acetamido-4-azasteroid derivatives as androgen receptor modulators |
| 12/21/2006 | US20060287325 Combinations of paroxetine and 2-(r)-(4-fluoro-2-methyl-phenyl)-4-(s)-((8as)-6-oxo-hexahydro-pyrrolo'1,2-a!-pyrazin-2-yl)-piperidine-1-carboxylicacid'1-(r)-(3,5-bis-trifluoromethyl-phenyl)- |
| 12/21/2006 | US20060287324 6-(2-Chlorophenyl)-7-(4-chlorophenyl)-N-cyclohexyl-[1,2,4]triazolo[4,3-b]pyridazin-3-amine; drug abuse, drug dependency; smoking cigarettes; appetite suppressants; antilipemic agents; anticholesterol agents; increasing high density lipoproteins;hypotensive agents; antidiabetic agents |
| 12/21/2006 | US20060287323 Regulation of appetite, antiemetics, immunosuppression, analgesia, inflammation, antinocioception, sedation, and intraocular pressure; synergistic; 2-(4-(Trifluoromethyl)benzyl)-7,8-bis(4-chlorophenyl)-6-(methylamino)-[1,2,4]triazolo[4,3-b]pyridazin-3(2H)-one |
| 12/21/2006 | US20060287322 Bicyclic heterocycles as cannabinoind-1 receptor modulators |
| 12/21/2006 | US20060287321 Novel Lactam Derivatives |
| 12/21/2006 | US20060287320 Preparation of thioarabinofuranosyl compounds and use thereof |
| 12/21/2006 | US20060287319 Anti-viral compositions comprising heterocyclic substituted phenyl furans and related compounds |
| 12/21/2006 | US20060287318 Method for treating glaucoma III B |
| 12/21/2006 | US20060287317 Sphingosine kinase inhibitors |
| 12/21/2006 | US20060287316 Method for improving pharmacokinetics of protease inhibitors and protease inhibitor precursors |
| 12/21/2006 | US20060287315 Pyrazinedicarboxamides and their use |
| 12/21/2006 | US20060287314 2-amino-4-morpholino-6-(4-acetanilide)pteridine; 2-amino-4-morpholino-6-(4-benzoylaminophenyl)pteridine; 2-amino-4-morpholino-6-(4-methylsulfonylaminophenyl)pteridine; 2-amino-4-morpholino-6-[3-Boc-(L)-phenylalanine-aminophenyl]pteridine; immunosuppressive; transplant rejection; antiinflammatory |
| 12/21/2006 | US20060287313 Isoquinoline compounds and methods of use thereof |
| 12/21/2006 | US20060287312 Tetracyclic amino and carboxamido compounds and methods of use thereof |
| 12/21/2006 | US20060287311 Tetracyclic Sulfonamide Compounds and methods of use thereof |
| 12/21/2006 | US20060287310 7-[4-(4-naphthalen-1-yl-piperazin-1-yl)-butoxy]-3,4-dihydro-1H-[1,8]naphthyridin-2-one; use in the treatment of central nervous system disorders, bipolar disorder in a human; chemical synthesis |
| 12/21/2006 | US20060287309 [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
| 12/21/2006 | US20060287308 3-Aminoquinazolin-2,4-dione antibacterial agents |
| 12/21/2006 | US20060287307 Antibacterial compounds |
| 12/21/2006 | US20060287306 Compounds to treat alzheimer's disease |
| 12/21/2006 | US20060287305 10th Carbon substitution with nitrogen heterocyclic group, halogen, or cycloalkyl or aryl group; stable agents against Plasmodium falciparum, Neospora caninum and Eimeria tenella which cause malaria, neosporosis and coccidiosis |
| 12/21/2006 | US20060287304 Dihydronaphthalene derivative compounds and agent comprising the derivative as active ingredient |
| 12/21/2006 | US20060287303 Modulators of muscarinic receptors |
| 12/21/2006 | US20060287302 Mitotic kinesin inhibitors |
| 12/21/2006 | US20060287301 Novel formulations for phenothiazines, including fluphenazine and its derivatives |
| 12/21/2006 | US20060287300 Anti-infective agents |
| 12/21/2006 | US20060287299 Combination therapy for dementia, depression and apathy |
| 12/21/2006 | US20060287298 Pharmaceutical for treatment of neurological and neuropsychiatric disorders |
| 12/21/2006 | US20060287297 Tricyclic opioid modulators |
| 12/21/2006 | US20060287296 Preparation of hymenialdsine derivatives and use thereof |
| 12/21/2006 | US20060287295 Antiproliferative agent in the prevention or treatment of tumors which are sensitive to inhibition of EGF and erbB receptor tyrosine kinases;1-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}methyl)-L-prolinamide |
| 12/21/2006 | US20060287294 Aspartyl protease inhibitors |
| 12/21/2006 | US20060287293 1-(4-{ethyl-[2-(4-methanesulfonylphenyl)-1-methylethyl]amino}butyl)-4-methanesulfonyl-[1,4]diazepan-2-one; repiratory system disorders: asthma and chronic obstructive pulmonary disease; nervous system, muscular,urogenital, gastrointestinal disorders; antiallergens; side effect reduction |
| 12/21/2006 | US20060287292 Histamine H3 receptor and serotonin transporter modulators; 4-(2-fluoro-phenyl)-7-(3-piperidin-1-yl-propoxy)-1,2,3,4-tetrahydro-[2,6]naphthyridine |
| 12/21/2006 | US20060287291 such as 2-Methoxy-5-methyl-N-[7-(piperazin-1-ylcarbonyl)-1-benzofuran-5-yl]benzenesulfonamide for treating disorders related to 5-HT6 receptor related disorders such as obesity, type II diabetes, anxiety, depression, panic attacks, memory/sleep/cognitive disorders, epilepsy, obsessive compulsive disorder |
| 12/21/2006 | US20060287290 Azabicyclic compounds are central nervous system active agents |
| 12/21/2006 | US20060287289 trihemihydrate crystal form of 7-[2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamide]-3-vinyl-3-cephem-4-carboxylic acid (cefdinir); powder diffraction pattern having 2 theta values of about 5.9 degrees , 8.1 degrees , 11.8 degrees , 15.7 degrees , 16.2 degrees , 22.6 degrees and 23.1 degrees; bactericide |
| 12/21/2006 | US20060287288 Antimicrobial composition useful for preserving wood |
| 12/21/2006 | US20060287287 Aminoacetamide acyl guanidines as beta-secretase inhibitors |
| 12/21/2006 | US20060287286 Prophylaxis of respiratory disorders and therapy, also metod of synthesis and composition with PDE4 inhibitor, corticosteroid hibitor or anticholinergic agent |
| 12/21/2006 | US20060287285 Methods and Compositions for the Treatment of Pain and Other Hormone-Allergy-Related Symptoms Using Dilute Hormone Solutions |
| 12/21/2006 | US20060287284 Pharmaceutical composition combining tenatoprazole and an anti-inflamatory agent |
| 12/21/2006 | US20060287283 Broad spectrum antibiotics; N-t-Butylcarbonyloxymethyl (9-[(2,2, dimethyl-propyl amino)-methyl]-minocycline)carbamate; antiinflammatory, anticarcinogenic, viricde, bactericide; gram positive and gram negative bacterial infection; viral infection; prodrugs |
| 12/21/2006 | US20060287282 Compositions comprising a SARM ad GnRH agonist or a GnRH antagonist, and methods of use thereof |
| 12/21/2006 | US20060287281 Phosphohalohydrins, process for the production thereof and use thereof |
| 12/21/2006 | US20060287280 N-[1-Carboxy-2-(1H-indol-3-yl)-ethyl]-3-(2-mercapto-acetylamino)-succinamic acid; zinc metallopeptidase inhibitors; promoting faster regeneration of bone mass after bone fractures, implantation of orthopedic and dental prostheses; osteogenesis stimulant; control phosphate metabolism |
| 12/21/2006 | US20060287279 Method of assaying an Fe-sugar complex |
| 12/21/2006 | US20060287277 water soluble, microparticulates; bone injuries |
| 12/21/2006 | US20060287276 administering methyl alpha manno-oligosaccharide and proanthocyanidins to treat enteric disorders selected from gastroenteritis, ulcerative colitis, diarrhoeal disease caused by pathogenic bacteria adhesion to mammalian intestinal epithelial cells |
| 12/21/2006 | US20060287275 Using 5'-sulfoxyoxy adenosine in therapy for tachycardia, cardiovascular disorders, angina, myocardial infraction , antilipemic agents |
| 12/21/2006 | US20060287274 Phosphoepoxides, method for making same and uses |
| 12/21/2006 | US20060287271 Prevention or treatment of disorders modulated by P2Y receptors such as type 2 diabetes, cystic fibrosis and cancer |
| 12/21/2006 | US20060287270 Methods of using redox-active surfactants to control polymer interactions |
| 12/21/2006 | US20060287269 Short interfering nucleic acid hybrids and methods thereof |
| 12/21/2006 | US20060287268 Splice-region antisense composition and method |
| 12/21/2006 | US20060287267 Controlling gene expression; viricides |
| 12/21/2006 | US20060287263 Methods and compositions for inducing antigen-specific immune responses |
| 12/21/2006 | US20060287261 Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides |
| 12/21/2006 | US20060287260 Oligonucleotides comprising a non-phosphate backbone linkage |
| 12/21/2006 | US20060287258 administering to the female an antibody that reduces the effect of prokineticin 1 on a prokineticin receptor to treat endometriosis; gonadotropin releasing hormone (GnRH) antagonist is selected from teverelix, abarelix, cetroelix or ganirelix antagonises the estrogen receptor |
| 12/21/2006 | US20060287257 Pharmaceutical compositions to treat diseases caused by mycobacterium |
| 12/21/2006 | US20060287256 Novel nutraceutical compositions and use thereof |
| 12/21/2006 | US20060287255 C-linked glucuronide of N-(4-hydroxybenzyl) retinone, analogs thereof, and method of using the same to inhibit neoplastic cell growth |
| 12/21/2006 | US20060287254 lowers concentration of sterol(s) other than cholesterol in plasma or tissue of mammal; comprising a sterol absorption inhibitor, a cholesteryl ester transfer protein (CETP) inhibitor; cardiovascular disorders |
| 12/21/2006 | US20060287253 Compounds and methods for treating seizure disorders |
| 12/21/2006 | US20060287251 Combination therapy for glycaemic control |
| 12/21/2006 | US20060287250 Intermediates: omega(1-haloalkoxycarbonylamino)alkanoates, e.g., Benzyl 1-{[(1-Chloroethoxy)carbonyl]aminomethyl}-1-Cyclohexane Acetate |
| 12/21/2006 | US20060287248 Asymmetric dosing methods |